These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Rapid PROTAC Discovery Platform: Nanomole-Scale Array Synthesis and Direct Screening of Reaction Mixtures. Plesniak MP; Taylor EK; Eisele F; Kourra CMBK; Michaelides IN; Oram A; Wernevik J; Valencia ZS; Rowbottom H; Mann N; Fredlund L; Pivnytska V; Novén A; Pirmoradian M; Lundbäck T; Storer RI; Pettersson M; De Donatis GM; Rehnström M ACS Med Chem Lett; 2023 Dec; 14(12):1882-1890. PubMed ID: 38116431 [TBL] [Abstract][Full Text] [Related]
23. PROTACs- a game-changing technology. Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491 [No Abstract] [Full Text] [Related]
24. Development of Stabilized Peptide-Based PROTACs against Estrogen Receptor α. Jiang Y; Deng Q; Zhao H; Xie M; Chen L; Yin F; Qin X; Zheng W; Zhao Y; Li Z ACS Chem Biol; 2018 Mar; 13(3):628-635. PubMed ID: 29271628 [TBL] [Abstract][Full Text] [Related]
25. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action. Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962 [TBL] [Abstract][Full Text] [Related]
26. Investigating the cell permeability of proteolysis-targeting chimeras (PROTACs). Yokoo H; Naito M; Demizu Y Expert Opin Drug Discov; 2023 Apr; 18(4):357-361. PubMed ID: 36908022 [No Abstract] [Full Text] [Related]
27. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera. Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151 [TBL] [Abstract][Full Text] [Related]
28. Solution Conformations Explain the Chameleonic Behaviour of Macrocyclic Drugs. Danelius E; Poongavanam V; Peintner S; Wieske LHE; Erdélyi M; Kihlberg J Chemistry; 2020 Apr; 26(23):5231-5244. PubMed ID: 32027758 [TBL] [Abstract][Full Text] [Related]
29. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC). Zhang H; Zhao HY; Xi XX; Liu YJ; Xin M; Mao S; Zhang JJ; Lu AX; Zhang SQ Eur J Med Chem; 2020 Mar; 189():112061. PubMed ID: 31951960 [TBL] [Abstract][Full Text] [Related]
30. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068 [TBL] [Abstract][Full Text] [Related]
31. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation. Wang X; Feng S; Fan J; Li X; Wen Q; Luo N Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774 [TBL] [Abstract][Full Text] [Related]
32. Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras. Lebraud H; Wright DJ; Johnson CN; Heightman TD ACS Cent Sci; 2016 Dec; 2(12):927-934. PubMed ID: 28058282 [TBL] [Abstract][Full Text] [Related]
33. Proteolysis-targeting chimeras for targeting protein for degradation. Qi J; Zhang G Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727 [TBL] [Abstract][Full Text] [Related]
34. Specific MHC-I Peptides Are Induced Using PROTACs. Jensen SM; Potts GK; Ready DB; Patterson MJ Front Immunol; 2018; 9():2697. PubMed ID: 30524438 [TBL] [Abstract][Full Text] [Related]
35. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review. Yang CY; Qin C; Bai L; Wang S Drug Discov Today Technol; 2019 Apr; 31():43-51. PubMed ID: 31200858 [TBL] [Abstract][Full Text] [Related]
36. Mapping the energy landscape of PROTAC-mediated protein-protein interactions. Villegas JA; Vaid TM; Johnson ME; Moore TW Comput Struct Biotechnol J; 2023; 21():1885-1892. PubMed ID: 36923472 [TBL] [Abstract][Full Text] [Related]
37. Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1. Hu M; Zhou W; Wang Y; Yao D; Ye T; Yao Y; Chen B; Liu G; Yang X; Wang W; Xie Y Acta Pharm Sin B; 2020 Oct; 10(10):1943-1953. PubMed ID: 33163345 [TBL] [Abstract][Full Text] [Related]
39. Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5. Rossi Sebastiano M; Doak BC; Backlund M; Poongavanam V; Over B; Ermondi G; Caron G; Matsson P; Kihlberg J J Med Chem; 2018 May; 61(9):4189-4202. PubMed ID: 29608068 [TBL] [Abstract][Full Text] [Related]
40. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery. Gu S; Cui D; Chen X; Xiong X; Zhao Y Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]